SLC6A4 polymorphisms and age of onset in late-life depression on treatment outcomes with citalopram: A sequenced treatment alternatives to relieve depression (STAR∗D) report

American Journal of Geriatric Psychiatry

Volumn 22, Issue 11, 2014, Pages 1140-1148

  Shiroma, Paulo R ^a   Drews, Maureen S ^b   Geske, Jennifer R ^b   Mrazek, David A ^b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b MAYO CLINIC   (United States)

Author keywords

citalopram; Depression; Sequenced Treatment Alternatives to Relieve Depression (STAR D); SLC6A4

Indexed keywords

CITALOPRAM; ANTIDEPRESSANT AGENT; SEROTONIN TRANSPORTER; SLC6A4 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEREDITY; HUMAN; INDEL MUTATION; INTRON; LATE LIFE DEPRESSION; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PROMOTER REGION; QUICK INVENTORY OF DEPRESSIVE SYMPTOMATOLOGY CLINICIAN RATING SCALE; RATING SCALE; REMISSION; SCORING SYSTEM; SLC6A4 GENE; TREATMENT OUTCOME; TREATMENT RESPONSE; CLINICAL TRIAL; DEPRESSIVE DISORDER, MAJOR; GENETICS; MIDDLE AGED; VARIABLE NUMBER OF TANDEM REPEAT;

AGE OF ONSET; AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; FEMALE; GENOTYPE; HUMANS; INTRONS; MALE; MIDDLE AGED; MINISATELLITE REPEATS; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; TREATMENT OUTCOME;

EID: 84927972867     PISSN: 10647481     EISSN: 15457214     Source Type: Journal    
DOI: 10.1016/j.jagp.2013.02.012     Document Type: Article

References (50)

1. Reynolds CF, Dew MA, Frank E, et al: Effects of age at onset of first lifetime episode of recurrent major depression on treatment response and illness course in elderly patients. Am J Psychiatry 1998; 155:795-799
2. Alexopoulos GS, Meyers BS, Young RC, et al: Clinically defined vascular depression. Am J Psychiatry 1997; 154:562-565
3. Dew MA, Reynolds CF, Houck PR, et al: Temporal profiles of the course of depression during treatment. predictors of pathways toward recovery in the elderly. Arch Gen Psychiatry 1997; 54: 1016-1024
4. Kalayam B, Alexopoulos GS: Prefrontal dysfunction and treatment response in geriatric depression. Arch Gen Psychiatry 1999; 56:713-718
5. Alexopoulos GS, Meyers BS, Young RC, et al: Recovery in geriatric depression. Arch Gen Psychiatry 1996; 53:305-312
6. Driscoll H, Basinski J, Mulsant B, et al: Late-onset major depression: Clinical and treatment-response variability. Int J Geriatr Psychiatry 2005; 20:661-667
7. Flint AJ, Rifat SL: Effect of demographic and clinical variables on time to antidepressant response in geriatric depression. Depress Anxiety 1997; 5:103-107
8. Baldwin RC, Benbow SM, Marriott A, et al: Depression in old age. A reconsideration of cerebral disease in relation to outcome. Br J psychiatry 1993; 163:82-90
9. Kozel FA,TrivediM,Wisniewski S, et al:Treatment outcomes for older depressed patients with earlier versus late onset of first depressive episode: A sequenced treatment alternatives to relieve depression (STAR∗D) report. Am J Geriatr Psychiatry 2008; 16:58-64
10. Kato M, Serretti A: Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry 2010; 15:473-500
11. Gerretsen P, Pollock B: Pharmacogenetics and the serotonin transporter in late-life depression. Expert Opin Drug Metab Toxicol 2008; 4:1465-1478
12. Murphy G, Hollander S, Rodrigues H, et al: Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Arch Gen Psychiatry 2004; 61:1163-1169
13. Durham LK, Webb S, Milos P, et al: The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder. Psychopharmacology 2004; 174:525-529
14. Nakamura M, Ueno S, Sano A, et al: The human serotonin transporter gene linked polymorphism (5-HTTLPR) shows ten novel allelic variants. Mol Psychiatry 2000; 5:32-38
15. Hu XZ, Lipsky RH, Zhu G, et al: Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. Am J Hum Genet 2006; 78:815-826
16. Hu XZ, Rush AJ, Charney D, et al: Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. Arch Gen Psychiatry 2007; 64:783-792
17. Mrazek DA, Rush AJ, Biernacka JM, et al: SLC6A4 variation and citalopram response. Am J Med Genet B Neuropsychiatr Genet 2009; 150B:341-351
18. Trivedi M, Rush AJ, Wisniewski S, et al: Evaluation of outcomes with citalopram for depression using measurement-based care in STAR∗D: Implications for clinical practice. Am J Psychiatry 2006; 163:28-40
19. Rush AJ, Fava M, Wisniewski S, et al: Sequenced treatment alternatives to relieve depression (STAR∗D): Rationale and design. Control Clin Trials 2004; 25:119-142
20. Sheline Y, Pieper C, Barch D, et al: Support for the vascular depression hypothesis in late-life depression: Results of a 2-site, prospective, antidepressant treatment trial. Arch Gen Psychiatry 2010; 67:277-285
21. Taylor WD: Influence of serotonin transporter promoter region polymorphisms on hippocampal volumes in late-life depression. Arch Gen Psychiatry 2005; 62:537-544
22. Porcelli S, Fabbri C, Serretti A: Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. Eur Neuropsychopharmacol 2012; 22:239-258
23. Furlong RA, Ho L, Walsh C, et al: Analysis and meta-analysis of two serotonin transporter gene polymorphisms in bipolar and unipolar affective disorders. Am J Med Genet 1998; 81:58-63
24. Gutierrez B, Pintor L, Gasto C, et al: Variability in the serotonin transporter gene and increased risk for major depression with melancholia. Hum Genet 1998; 103:319-322
25. Sarosi A, Gonda X, Balogh G, et al: Association of the STin2 polymorphism of the serotonin transporter gene with a neurocognitive endophenotype in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32:1667-1672
26. Zanardi R, Benedetti F, Di Bella D, et al: Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. J Clin Psychopharmacol 2000; 20:105-107
27. Serretti A, Kato M, De Ronchi D, et al: Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry 2007; 12:247-257
28. Meltzer CC, Smith G, DeKosky ST, et al: Serotonin in aging, late-life depression, and Alzheimer's disease: The emerging role of functional imaging. Neuropsychopharmacology 1998; 18:407-430
29. Greenberg BD, Tolliver TJ, Huang SJ, et al: Genetic variation in the serotonin transporter promoter region affects serotonin uptake in human blood platelets. Am J Med Genet 1999; 88:83-87
30. Smith GS, Kahn A, Sacher J, et al: Serotonin transporter occupancy and the functional neuroanatomic effects of citalopram in geriatric depression. Am J Geriatr Psychiatry 2011; 19:1016-1025
31. Smith GS, Workman CI, Kramer E, et al: The relationship between the acute cerebral metabolic response to citalopram and chronic citalopram treatment outcome. Am J Geriatr Psychiatry 2011; 19:53-63
32. Smith G, Lotrich F, Malhotra A, et al: Effects of serotonin transporter promoter polymorphisms on serotonin function. Neuropsychopharmacology 2004; 29:2226-2234
33. Sneed JR, Culang-Reinlieb ME: The vascular depression hypothesis: An update. Am J Geriatr Psychiatry 2011; 19:99-103
34. Baldwin RC, Tomenson B: Depression in later life. A comparison of symptoms and risk factors in early and late onset cases. Br J Psychiatry 1995; 167:649-652
35. Krishnan KR, Hays JC, Blazer DG: MRI-defined vascular depression. Am J Psychiatry 1997; 154:497-501
36. Taylor WD, Macfall JR, Boyd B, et al: One-year change in anterior cingulate cortex white matter microstructure: Relationship with late-life depression outcomes. Am J Geriatr Psychiatry 2011; 19: 43-52
37. Alexopoulos GS, Murphy CF, Gunning-Dixon FM, et al: Serotonin transporter polymorphisms, microstructural white matter abnormalities and remission of geriatric depression. J Affect Disord 2009; 119:132-141
38. Comings DE, MacMurray JP, Gonzalez N, et al: Association of the serotonin transporter gene with serum cholesterol levels and heart disease. Mol Genet Metab 1999; 67:248-253
39. Nakatani D, Sato H, Sakata Y, et al: Influence of serotonin transporter gene polymorphism on depressive symptoms and new cardiac events after acute myocardial infarction. Am Heart J 2005; 150:652-658
40. Whyte EM, Pollock BG, Wagner WR, et al: Influence of serotonintransporter-linked promoter region polymorphism on platelet activation in geriatric depression. Am J Psychiatry 2001; 158: 2074-2076
41. Williams RB, Marchuk DA, Gadde KM, et al: Central nervous system serotonin function and cardiovascular responses to stress. Psychosom Med 2001; 63:300-305
42. Salloway S, Boyle P, Correia S, et al: The relationship of MRI subcortical hyperintensities to treatment response in a trial of sertraline in geriatric depressed outpatients. Am J Geriatr Psychiatry 2002; 10:107
43. Bremner JD: Does stress damage the brain? Biol Psychiatry 1999; 45:797-805
44. Glatz K, Mossner R, Heils A, et al: Glucocorticoid-regulated human serotonin transporter (5-HTT) expression is modulated by the 5-HTT gene-promotor-linked polymorphic region. J Neurochem 2003; 86:1072-1078
45. Mössner R, Daniel S, Albert D, et al: Serotonin transporter function is modulated by brain-derived neurotrophic factor (BDNF) but not nerve growth factor (NGF). Neurochem Int 2000; 36: 197-202
46. Banasr M, Duman RS: Regulation of neurogenesis and gliogenesis by stress and antidepressant treatment. CNS Neurol Disord Drug Targets 2007; 6:311-320
47. Hsieh M, McQuoid D, Levy R, et al: Hippocampal volume and antidepressant response in geriatric depression. Int J Geriatr Psychiatry 2002; 17:519-525
48. Hariri A, Mattay V, Tessitore A, et al: Serotonin transporter genetic variation and the response of the human amygdala. Science 2002; 297:400-403
49. Pezawas L, Meyer-Lindenberg A, Drabant E, et al: 5-HTTLPR polymorphism impacts human cingulate-amygdala interactions: A genetic susceptibility mechanism for depression. Nat Neurosci 2005; 8:828-834
50. Rausch J, Johnson M, Fei Y, et al: Initial conditions of serotonin transporter kinetics and genotype: Influence on SSRI treatment trial outcome. Biol Psychiatry 2002; 51:723-732